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Abstract
Lung cancer is the cause of most cancer-related deaths in the Western world. Non-small cell lung cancer accounts for almost
80% of all lung cancers, and 50% of this type are adenocarcinomas. The cellular and molecular origin of this type of lung
cancer remains elusive and the mechanisms are poorly known. It is known that K-Ras mutations appear in 25–30% of lung
adenocarcinomas and it is the best known single mutation that can be related to lung cancers. Recently, it has been
suggested that a putative population of mouse bronchioalveolar stem cells could be considered as the cell of origin of
adenocarcinomas. These cells are expanded in the early stages of lung tumorigenesis. We have isolated a population of
mouse bronchioalveolar stem cells and induced their transformation by oncogenic K-RasG12. Different approaches have
shown that an intracellular network linking the p38a MAPK and the PI3K-Pdk1 pathways is involved in regulating the
survival and malignant progression of the transformed cells. Absence of p38a catalytic activity leads to further Pdk1
activation (independent of Akt and Erk activity), enhancing the survival and proliferation of the more malignant lung cancer
cells. This specifically selects high Sca-1/Sox9 cells that harbour a stronger colonizing potential, as they maintain their
capacity to produce secondary tumors after serial transplantations.
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Introduction
Lung cancer is the main cause of all cancer deaths in the world
[1]. However, after many years of research, very little is known
about the cellular and molecular mechanisms involved in this type
of cancer. The existence of a population of lung cells that could be
the source of the major types of lung cancers has been studied in
recent years, but still remains elusive and very controversial.
Recently, different studies in animal models have suggested the
existence of a population of bronchioalveolar stem cells that could
act as the cell of origin [3,4]. These cells are expanded in the first
stages of lung tumorigenesis induced by oncogenes. However, the
mechanisms that promote these cells to transformation, and their
progression to malignant stages are still poorly understood [5].
Using a mouse model of lung cancer induced by oncogenic K-
RasG12, we have previously determined the role of the p38a
pathway opposing the initiation and progression of the tumori-
genic process [4]. This kinase promotes differentiation factors that
act as negative regulators of tumorigenesis (e.g. C/EBPa), while
reducing proliferation of lung stem cells. Human lung tumours
show a selection of cells with low levels of p38a protein [4]. To
further study the progression of lung cancer and define the
mediators of that repressive role by p38a, we have isolated
putative stem cells from mouse lungs with a specific expression
profile (Sca-1+/E-Cadherin+/CD312/CD342/CD452/CD732).
These cells can be indefinitely expanded in culture and
transformed by expression of a K-RasG12 mutant.
In this manuscript we have studied, in vitro and in vivo, the
process of transformation of the lung stem cells and the
mechanisms involved in the selection of tumour cells with low
levels of p38a, and the functional advantages that low p38 activity
provides to the progression of lung cancer to more malignant
stages.
Materials and Methods
Cell Isolation and Cell Culture
Mouse lung tissues from wild-type or LSL-K-rasG12D –TetO-sftpc-
Cre C57BL/6 mice were disassociated by finely mincing with a
razor blade and by incubating in Dulbecco’s modified Eagle’s
medium (DMEM, PAA) containing collagenase (3 mg/mL,
Worthington Biochemical) for 30 minutes at 37uC in a shaking
incubator. The resulting cell suspension was submitted to a series
of three filtrations (two through a 70-mm strainer and the last one
through a 40-mm strainer). Then cells were FACS sorted to select
Sca1+/E-Cadherin+/CD312/CD342/CD452/CD732 cells.
Sorted Sca1+ cells were used for SC injections or re-suspended
in DMEM supplemented with 10% fetal bovine serum (FBS,
PAA), insulin (50 ug/mL, Peprotech), EGF (10 ng/mL, Pepro-
tech), FGF2 (10 ng/mL, Peprotech) and 1% penicillin/strepto-
mycin (PAA). After two days, the medium was changed for serum
free DMEM/F12 (ratio 1:1) supplemented with 1% N2, 2% B27
serum (Gibco), EGF (10 ng/mL) and FGF2 (10 ng/mL). Cells
were seeded in normal culturing plates.
The medium was changed every two days and once a week an
accutase (PAA) treatment was perform to disassociate spheres.
Cells were grown in a 7% CO2 incubator at 37uC.
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Figure 1. In vitro and in vivo characterization of bronchioalveolar and K-Ras WT or G12 expressing lung stem/progenitor cells. Mouse
lung bronchioalveolar stem cells were isolated negatively sorting for hematopoietic, endothelial and mesenchymal markers and positive for E-Cad/
Sca1. (A) Immunofluorescence staining shows that freshly sorted (upper), or clonally derived cells cultured for 30 passages (lower) express Sca1 and E-
Cadherin. (B) Freshly sorted (upper) or clonally cultured cells (lower) have the potential to generate bronchioalveolar tissue in kidney capsule
transplants. (C) Clonally culture stem/progenitor cells (passage 3) were transfected with K-RasWT, K-RasG12 and/or p38AGF (dominant negative)
vectors. (D) H&E staining of kidney capsule outgrowths produced by K-RasWT or K-RasG12 cells at different passages. (E) K-RasG12 infected cells
maintain E-Cad and Sca1 expression after passage 4.
doi:10.1371/journal.pone.0078911.g001
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Mouse K-Ras tumor cells derived from LSL-K-rasG12D –TetO-
spc-Cre lung adenocarcinomas were isolated from 15 week tumors
following the above mentioned protocol and then sorted for Sca1
and used for SC injections.
Retroviral Infection
Retroviruses were produced according to a protocol from the
Weinberg’s lab (Addgene). One of the retroviral plasmid vectors
(pBabe-K-RasWT-GFP, pBabe-KRasG12V-GFP and pBabe-
p38AGF) and the packaging plasmids (M57 and pMD.G2) were
co-transfected using CaPO4 precipitation (Invitrogen) into the
packaging cell line 293T. Viral supernatants were collected 48
hours later, filtered through 0.45-mm filters and concentrated using
Spin-XH UF concentrators (100 KD MWCO, Corning). After
selection by cell sorting on GFP positive cells, K-RasWT and
G12V cells have been infected with pBabe-p38AGF. 48 hours
after infection, 5 ug/mL of puromycin were added to the medium.
Flow Cytometry Analysis
All staining were performed in PBS (PAA) with 1% BSA
(Sigma). Antibodies used are listed below: Sca-1 (PE-conjugated)
and E-Cadherin (Alexa 647-conjugated) purchased from Biole-
gend; CD34 (FITC-conjugated), CD31 (FITC-conjugated) and
CD45 (FITC-conjugated) from BD Pharmingen and CD44
(PerCP-Cy5.5-conjugated) from eBiosciences. Flow cytometry
analyses were performed on a MoFlo cytometer (Dako). All data
were analysed with FlowJo software (Tree Star).
Mouse Experiments
All animal experimentations were performed in accordance
with the terms of UK Home Office guidelines. The home office
project license number under which these experiments were
conducted is PPL 80/2188. CD1 nude male mice were obtained
from Charles Rivers Laboratories.
Ten week old mice received subcutaneous injection in each
flank of 104 cells. Animals were monitored daily. Tumour volume
was measured using an electronic digital calliper and calculated as
an ellipsoid [6,7].
Subcutaneous tumours formed after injection of cells were
removed. Pictures were taken under microdissection microscope
(brightfield and GFP). A part of each tumours were fixed in 4%
paraformaldehyde for 24 hours at 4uC, then placed in 30%
sucrose overnight prior to embedding the tissue in OCT (Sakura).
Slides were stained in hematoxylin and eosin (H&E Dako) or with
Ki67 (Vector Labs) according to the manufacturer’s instructions.
Images were acquired by using a Zeiss Apotome microscope.
Each tumour was disassociated to obtain single-cell suspension.
For that, tumour tissues were disassociated mechanically and
enzymatically. Tumors were minced with a razor blade and
incubated in accutase at 37uC for 10 minutes. The tissues were
further dissociated by pipette trituration and filtered through a 70-
mm strainer. Then cells were re-suspended in DMEM/F12 (ratio
1:1) supplemented with 1% N2, 2% B27 serum, EGF (10 ng/mL)
and FGF2 (10 ng/mL).
Total RNA Isolation, Reverse Transcription and PCR
Total RNAs were extracted using TRIzol (Invitrogen) according
to manufacturer’s instructions. The RNA solutions were treated
with RNase-free DNase I (Promega) to remove trace of genomic
DNA contamination. Total RNAs (1 ug) of each sample were
reverse transcribed into cDNAs using the iScript cDNA synthesis
kit (Bio-Rad) containing oligo(dT) according to the manufacturer’s
instructions. Reactions were carried out using a Mastercycler
Gradient (Eppendorf) under the parameters and primers described
as following: 94uC for 30 s, 49uC for 30 s, and 72uC for 30 s for 30
cycles with sense 59-CTTTATCCAGCCCTCAC-39 and anti-
sense 59-ACCCTAACTGACACACATTCC-39 for p38AGF;
94uC for 30 s, 53.2uC for 30 s, and 72uC for 30 s for 30 cycles
with sense 59-CTTGTGGTGGTTGGAGCTGTA-39 and anti-
sense 59-CTCCCCAGTTCTCATGTACTGG-39 for K-
RasG12V.
Quantitative Real-Time PCR
cDNA products were used for further performance of the
quantitative real-time PCR (qPCR) under the conditions and
primers described as followings: initial denaturation at 95uC for
20 s followed by 40 cycles with denaturation at 95uC for 3 s,
annealing at 60uC for 30 s and elongation at 68uC for 20 s. The
primers used in the experiments were sense 59-AGTACCCG-
CATCTGCACAAC-39 and anti-sense 59-AC-
GAAGGGTCTCTTCTCGCT-39 for sox9;; sense 59-
AGGTCGGTGTGAACGGATTTG-39 and anti-sense 59-
TGTAGACCATGTAGTTGAGGTCA-39 for gapdh; sense 59-
GGCTGTATTCCCCTCCATCG-39 and anti-sense 59-
CCAGTTGGTAACAATGCCATGT-39 for beta-actin. All sam-
ples were analyzed in triplicate by Fast SYBR green master mix
(Applied Biosystems) using a Mastercycler ep realplex2 real-time
PCR machine (Eppendorf). Relative gene quantification was
performed using the DDCT method.
Viability, Cell Cycle and Cell Death Analysis
Cell viability assays were done with a Vi-CELL XR cell viability
analyzer with Vi-CELL XR 2.03 software (Beckman Coulter). The
small chemical inhibitors used are Akt Inhibitor 1/2 (AI, Sigma) at
10 mM, PI3Kinase Inhibitor (LY294002 or LY, Sigma) at 20 mM,
and DMSO (Sigma) as control.
Cells were incubated with 10 mM EdU at 37uC for 120 minutes.
The cells were then accutase treated, and fixed in 4% parafor-
maldehyde. EdU incorporation was determined with the Click-iT
EdU Alexa Fluor 647 flow cytometry assay kit (Molecular Probes)
according to the manufacturer’s instructions. For each population,
a minimum of 104 cells was counted. Cells were analysed on
Fortessa flow cytometer (Becton Dickinson) using FACSDiva
software and data analyses were performed with FlowJo software.
Apoptosis was determined by Annexin V-APC/Dapi staining
using Apoptosis Detection Kit (BD Pharmingen). These assays
were performed according to manufacturer’s instructions. For
each population, a minimum of 104 cells was counted. Cells were
analysed on Fortessa flow cytometer (Becton Dickinson) using
FACSDiva software and data analyses were performed with
FlowJo software.
Anchorage-Independent Growth Assays
5000 cells/well were seeded in six-well plates within a top layer
of 0.3% agar and a bottom layer of 0.6% agar. After the top layers
were solidified, 1 mL of media was added. During the incubation,
the plates were checked every day and media replenished each
3 days. Plates were stained with 0.005% crystal violet for 1 hour,
and the colonies were counted.
Western-Blotting
Cell lysates were prepared with RIPA buffer (50 mM Tris-HCl,
pH7.5, 150 mM NaCl, 1.0% Triton X-100, 0.1% SDS, 1%
sodium deoxycholate, 1 mM pervanadate, protease inhibitor
cocktail tablet (Roche Diagnostics Ltd)) on ice for 1 hour. 30 mg
of the total protein was applied to a SDS-PAGE, transferred to
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Figure 2. Molecular and functional characterization of K-RasWT and K-RasG12 infected bronchioalveolar stem/progenitor cells. (A)
Flow cytometry plots showing the expression of the stem cell markers Sca-1 (upper) and CD44 (lower) in cells stably expressing K-RasWT, K-RasG12
and the dominant-negative p38AGF 4–6 weeks after the infection with the corresponding constructs. The plots show a representative experiment of
5 different made in triplicates. K-RasWT, K-RasG12 and K-RasG12+AGF, p#0.01; K-RasWT+AGF, p#0.05. (B) p38 inhibition collaborates with K-RasG12
transformation to increase cell viability of lung stem/progenitor cells. (C) Absence of p38 activity specifically increases soft agar colony forming
potential of transformed K-RasG12 lung stem/progenitor cells. (D) p38 deficiency constitutively activates the PI3K pathway, increasing P-Pdk1 and P-
Akt but not P-Pten levels.
doi:10.1371/journal.pone.0078911.g002
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Figure 3. PI3K-Pdk1 dependent survival of K-RasG12 transformed lung stem/progenitor cells selects for CD44+/Sca-1+ populations.
(A) Protein levels of the stem cell marker Sox9 are reduced by PI3K inhibition in K-RasG12 transformed lung stem/progenitor cells. PI3K inhibition, but
not specific Akt inhibition, reduces the Pdk1 constitutive activation in K-RasG12 cells deficient in p38 signalling. (B) Survival levels of K-RasWT and/or
K-RasG12 lung stem cells with or without active p38. (C) PI3K inhibition increases classic apoptosis of oncogene transformed lung stem/progenitor
but not K-RasWT cells. (D) Absence of p38 signalling selects for high CD44+/Sca-1+ expressing K-RasG12 cells. PI3K inhibition significantly and
specifically increased cell death of p38-deficient oncogenic cells. The plots are from a representative experiment of 7 different made in triplicates. P
value: p#0.01 to p#0.03.
doi:10.1371/journal.pone.0078911.g003
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PVDF membrane (Millipore) and blocked for 1 hour in blocking
buffer (5% BSA). Blots were incubated overnight at 4uC with
primary antibodies in blocking buffer. The primary antibodies
used were: anti-Cyclin D1, purchased from Santa Cruz Biotech-
Figure 4. Cellular characterization of Subcutaneous Tumors induced by K-RasG12 transplanted cells. (A) Transformed K-RasG12 (+/
2p38AGF) cells (passage 4) used for subcutaneous (SC) injections express epithelial and lung specific markers. (B) H&E staining of SC tumours
induced by K-RasG12 (+/2p38AGF) cells. (C) Immunostaining of K-RasG12-induced SC tumors with epithelial (E-Cad), lung (TTF-1, SP-C, CC-10, AQ5),
stem (Sca1) or mesenchymal (Vimentin) markers. (D) Cells isolated from K-RasG12-induced SC tumors express different levels of epithelial and lung
specific markers.
doi:10.1371/journal.pone.0078911.g004
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Figure 5. Sca-1 level determine a differential tumorigenic potential of K-RasG12 transformed lung stem cells. (A) Distinct Sca-1
populations in K-RasG12 transformed stem/progenitor cells based on p38 signalling. (B) Lack of p38 signalling and higher Sca-1 levels in K-RasG12
cells correlate with increased potential to produce subcutaneous tumours. One-Way ANOVA test p#0.05. (C) H&E images of subcutaneous tumors
induced by different populations of K-RasG12 or K-RasG12+AGF with low, medium or high levels of Sca-1. Right panels show Ki67 expression and GFP
detection of injected cells (scale bar 50 mM). (D) Bar graph showing the Ki67 expression of Sca-1 populations of K-RasG12 WT or AGF. A representative
graph of 3 to 5 independent experiments is shown, 6SD.
doi:10.1371/journal.pone.0078911.g005
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nology; anti-p38, anti-Akt, anti-pAkt Ser473, anti-pPdk1 Ser241,
anti-Pten, anti-pPten Ser380 from Cell Signaling Technology;
anti-Sox9 from Millipore, anti-pERK1/2 from Promega and anti-
Tubulin from Sigma. IR-dye-labelled secondary antibodies (LI-
COR) were applied at 1:15000 for 1 hour. All blots were imaged
using the Odyssey infrared scanner (LI-COR). Each western-blot
was repeated at least three times.
Figure 6. Tumorigenic progression selects for CD44+/Sca-1+ cells and is promoted in absence of p38 signalling. (A) Tumor morphology
and Ki67 expression in serial subcutaneous injections of K-RasG12 and K-RasG12+AGF cells (scale bar 50 mM). n = 10, 1st transplant; n = 8, 2nd
transplant (B) Flow cytometry plots showing CD44 and/or Sca-1 expression in K-RasG12 or K-RasG12+AGF isolated from sequential tumours and the
same populations after PI3K inhibition for 72 hours. 1st transplant, n = 10, p#0.01; 2nd transplant, n = 8, p#0.05.
doi:10.1371/journal.pone.0078911.g006
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Results
Molecular and Functional Characterization of in vitro
Expanded K-Ras-transformed Bronchioalveolar Stem Cells
As previously published [4], putative lung stem cells were
isolated from mouse bronchioalveolar epithelium using a negative
(CD312/CD342/CD452/CD732) and a positive (E-Cadherin+/
Sca-1+) selection (Fig. 1A). Clonally derived cells can be cultured
and maintain the epithelial (E-Cad) and stem (Sca1) cell markers
(Fig. 1A). The cultured cells retain a similar differentiation
potential as the freshly isolated cells as shown by kidney capsule
transplants (Fig. 1B). These cells grow in spheres in culture and
single cell clones can be indefinitely expanded while expressing
lung specific and stem cell markers (Fig. S1A and S1B). To study
oncogenic transformation, clonally expanded cells were stably
transfected with retroviral vectors expressing K-RasWT or mutant
K-RasG12. In addition, the cells were co-infected with retroviral
vectors expressing a dominant negative mutant form of p38a
(p38AGF) that inhibits the pathway (Fig. 1C and Fig. S1C). K-
RasWT infected cells retain the potential to generate a
bronchioalveolar epithelium in kidney capsule transplants after 8
passages, but the transformed K-RasG12 infected cells give rise to
an undifferentiated tissue with tumorigenic features (Fig. 1D). The
K-RasG12 infected cells still express the selection markers (E-
Cad/Sca1) at passage 4 (Fig. 1E).
There is an in vitro differential selection of Sca-1 cells; whereas
the WT K-Ras cells maintain higher levels of putative progenitor/
stem cells (Sca-1+), the oncogenic-induced transformation lowers
the Sca-1+ population. However, inhibition of the p38a pathway
produces the converse selection, reducing Sca-1+ WT cells and
increasing that population of transformed K-RasG12 cells
(Fig. 2A). The expression of the cell adhesion molecule CD44
recently described as able to promote Ras-mediated MAPK
signaling [8] is not affected, although is higher in the K-RasG12
cells (Fig. 2A).
Deficiency of p38 signal increases the survival of WT and
transformed cells, but is significantly higher in the K-RasG12 cells
(Fig. 2B). The p38-dependent increased survival is independent of
canonical apoptosis (Fig. S1D) and proliferation induced by K-
RasG12 (Fig. S1E). However, lack of p38 signalling specifically
promotes anchoring-independent growth in soft agar (a hallmark
of cellular transformation), of oncogenic but not of WT cells
(Fig. 2C). Correlating to the transforming capacity, absence of p38
activity induces an upregulation of the expression of the stem and
lung cancer marker Sox9 [9,10] in K-RasG12 cells (Fig. 2D and
Fig. S1F) supporting its potential as a therapeutic target.
p38 Crosstalk with PI3K-Pdk1 is Involved in Stem Cell
Selection
It has been reported by others and us that p38a signalling
deficiency results in constitutive activation of other kinase
pathways such as JNK, ERK or AKT [4]. To test the possible
mediation of any of these pathways in the functional role of p38a
in lung stem cell transformation, we used different small chemical
inhibitors. The ERK and PI3K pathways are major mediators of
oncogenic K-Ras induction of transformation. A chemical
inhibitor of PI3K was able to repress Sox9 protein levels in
transformed cells deficient or not in p38 signal (Fig. 3A). Also the
inhibition of PI3K activity, but not Akt, efficiently reduced Akt
and Pdk1 constitutive activation in absence of p38 signalling
(Fig. 3A) when Akt inhibition itself only marginally reduced cell
viability (Fig. 3B). However, inhibition of PI3K almost completely
abrogated cell viability (Fig. 3B), in part due to an increase in
canonical apoptosis (Fig. 3C). Therefore, Pdk1 but not Akt is
mediating the increased survival of oncogenic transformed lung
stem cells. In addition, the mostly Sca-1+/CD44+ p38-deficient
transformed lung stem cells are more sensitive to PI3K induced
cell death than the WT or K-RasG12 cells with normal p38
signalling (Fig. 3D). Interestingly chemical inhibition of ERK did
not affect Pdk1 activation (data not shown) weakening the
hypothesis of a potential cross-talk between these two related
pathways.
Sca-1 is a Marker of Tumorigenic Potential for K-RasG12
Transformed Lung Progenitor/Stem Cells
Deficient p38a signalling selected K-RasG12 transformed cells
for a more stem cell profile with higher in vitro transforming
potential. We tested the in vivo tumorigenic capacity of these cells
using subcutaneous (SC) injections in nude mice. For the injections
we used clonally derived cells expressing K-RasG12 at passage 4
after infection. These cells maintained the expression of lung and
epithelial markers (Fig. 4A). Injected K-RasG12 and K-RasG12+-
p38AGF cells (104 cells) formed subcutaneous tumors (Fig. 4B).
Neither non-infected or K-RasWT cells were able to grow when
SC injected (data not shown). K-RasG12 SC tumors were formed
by cells expressing epithelial (E-Cad), stem (Sca1) and lung specific
(TTF-1, SP-C, CC-10, AQ5) markers, but not the mesenchymal
marker vimentin (Fig. 4C). Cells isolated from SC tumors
confirmed different expression levels of epithelial and lung specific
markers (Fig. 4D).
Based on different levels of Sca-1 expression, we sorted K-
RasG12 or K-RasG12+p38AGF (K-RasG12+AGF) populations
with low, medium or high level of expression of that stem cell
marker (Fig. 5A). Cells from every population (104 cells) were
subcutaneously injected in nude mice. As a control, K-RasWT
cells were injected but did not induce any tumors. Mice were
sacrificed for humanitarian reasons when the animals showed
distressful behaviour. After 18 days, most K-RasG12+AGF
injected animals had to be sacrificed. At this time, it was obvious
that the size of the tumors correlated with higher Sca-1 expression
cells (Fig. 5B). Of the K-RasG12, only the high Sca-1 cells
produced tumors at day 18, but not the low and medium Sca-1
expressing cells. Only after 28 days all K-RasG12 populations
generated tumors, and the size also correlated with the level of
Sca-1 expression (Fig. 5B). The morphology of the tumors was also
distinct based on the lack of p38 activity and Sca-1 expression. All
p38-deficient cells showed loose and not well encapsulated
tumours with high vascularisation (Fig. 5C right). On the other
hand, the p38 active tumors were well-delimited and less
vascularised (Fig. 5C left). Cells with high Sca-1 expression
Figure 7. Mouse and Human Adenocarcinomas show a correlate Sca1 selection to p38a deficiency, increased P-Pdk1 and malignant
progression. (A) Flow cytometry analysis of CD44 and Sca1 expression of tumor mouse LSL-K-Ras cells before (blue) and after (red) SC induced
tumors. (B) Mouse LSL-K-RasG12 (Sca1+) tumor cells were sorted for different levels of Sca1 expression and SC injected in nude mice (104 cells). The
graph depicts the evolution of tumor volumes show in the below table at 10 or 28 days after transplantation. One-Way ANOVA test p#0.05. (C)
Immunostaining of tissue samples showing H&E and the expression of p38a (centre) and P-Pdk1 (low) in K-Ras mutant early (stage 1) or late
(metastatic) human lung adenocarcinomas. Graph shows the relative intensity of p38a and P-Pdk1 expression in the tumor (T) areas versus the
expression in the background (B) tissue. Stage 1, n:13; Metastatic, n:9, are depicted.
doi:10.1371/journal.pone.0078911.g007
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showed a poorly differentiated morphology, and that was
enhanced in the tumors lacking p38 signal. Interestingly, the
percentage of Ki67 proliferating cells is higher in the tumors with
p38 activity and low level of Sca-1 expression (Fig. 5D).
p38 Opposes the Tumorigenic Selection for More Stem
Cell-like Aggressive Tumor Cells
The more invasive and malignant properties of the transformed
lung stem cells lacking p38 activity were obvious after serial tumor
inductions (Fig. 6A and Fig. S2A). Transformed cells expressing a
GFP reporter (green) were isolated from subcutaneous tumor,
sorted and directly injected subcutaneously in nude mice. Serial
tumors showed again more vascularized and less differentiated
tissue in p38-deficient cells (Fig. 6A). Cells isolated from tumors
were used for in vitro soft agar assays. K-RasG12 cells increased
their potential to form colonies after serial tumorigenesis, but that
was especially obvious for the cells lacking p38 signalling (Fig.
S2A). On the other hand, K-RasWT cells failed to induce tumors
or produce colonies in soft agar (Fig. 2C and data not shown). The
increase in transforming potential gained by K-Ras oncogenic cells
in serial injections correlates with higher expression of the stem cell
marker Sox9 whereas there is no modification of the CyclinD1
expression level (Fig. S2B). Oncogenic K-RasG12 cells lacking p38
signalling were selected for cells with higher levels of stem cell
markers CD44 and Sca-1 expression than their counterparts with
a normal p38 activity (Fig. 6B). That selection is prevented by
inhibition of PI3K and especially is active in reducing the CD44+/
Sca-1+ population of p38-deficient K-RasG12 cells from 1st or 2nd
induced tumorigenesis. Cells in 2nd injection SC tumors did not
express non-epithelial markers (Fig. S2C) but still expressed the
lung specific marker SP-C (Fig. S2D). Furthermore, only the K-
RasG12 cells from secondary tumors are sensitive to PI3K
inhibition reducing the selection to Sca-1 cells (Fig. 6B). Moreover,
these two transformed cell populations are able to colonise lungs
and to form lung tumors and once again p38 inhibition increases
the tumorigenic potential in the lung of K-RasG12 as shown in tail
vein injections (Fig. S2F).
Sca1-dependent selection of K-Ras tumor cells during tumor-
igenic progression was confirmed using tumor cells from a LSL-K-
rasG12D –TetO-sftpc-Cre mouse model of lung adenocarcinoma [11].
Cells from 15-week old tumors were sorted for Sca-1 expression
and directly used for SC injections. Cells isolated from 20 days old
SC tumors express higher levels of Sca1 than the LSL-K-Ras
tumor cells used for the injections (Fig. 7A). LSL-K-RasG12 (15
week) tumor cells were also differentially sorted in low, medium or
high Sca1 levels and injected SC in nude mice. Sca1 expressing
levels determined a differential potential to induce tumors in time
and size (Fig. 7B), confirming the results observed with the
transformed cells in culture.
Selection of p38a deficient cells was previously shown in human
lung cancers [4]. Histological analysis of samples from human
adenocarcinomas carrying mutant K-Ras12 at different stages of
cancer progression, have shown a correlation between loss of
p38a, activation of Pdk1 (pPdk1) within the tumors and
progression of human lung adenocarcinomas into malignant
stages (Fig. 7C). Thus, we confirmed that pPdk1-dependent
selection of more malignant Sca-1 cells is a common mechanism
during adenocarcinoma progression in mouse and human lung
cancers.
Discussion
The cellular progression of cancer cells into malignant stages is
still poorly understood [12]. Loss of differentiation markers and
morphology are some of the hallmarks of lung cancer development
(e.g. from adenomas to adenocarcinomas) [11]. It is known that
accumulation of mutations happens during the malignant
progression [12]. However, most of the mutations in lung cancer
either play a small role or none at all [13]. Oncogenic (G12) K-
Ras is present in an important percentage of lung cancers and
especially in adenocarcinomas [1]. Some of the pathways involved
in K-Ras signalling are well-known and drugs directed against
molecules at different levels of these pathways (e.g. ERK, PI3K,
AKT or mTOR) are already being used in the clinic or
undergoing clinical trials [2]. Nevertheless, the efficiency of these
drugs has been very limited and has not fulfilled the expectations.
One of the problems in cancer therapy is the existence of small
populations of cells resistant to the treatment that relapses as more
virulent and malignant than the previous tumor [14].
We have studied the malignant progression in mouse lung
cancer using a population of cells that has previously proposed to
be a putative cell of origin of cancer [3,4]. Lung cells were
transformed inducing the expression of a mutant K-RasG12 [15].
These transformed cells are able to colonize the lungs produced
subcutaneous tumors, harbouring the potential to induce sen-
condary tumors after transplantation. Our data supports the role
of the p38 MAPK pathway opposing undifferentiation promoted
by transformation [4]. Deficient p38 signalling is accompanied by
constitutive activation of PI3K and ERK pathways [4]. It is the
PI3K-Pdk1 pathway, but not Akt or Erk what increases the
survival of more stem-like cells with higher levels of the stem and
cancer markers Sca-1, CD44 and Sox9, in absence of p38 activity.
Previous studies suggest Sox9 and Sca1 as potential therapeutic
target and marker of tumorogenicity respectively. Interestingly, in
our context, expression of these proteins are also related to the
severity/efficiency of the oncogene K-Ras (+/2 p38 activity).
Inhibition of the PI3K-Pdk1 axis specially affects the high CD44+/
Sca-1+ population, increasing cell death and reducing cell
proliferation. This is important as higher Sca-1 expression cells
have more potential to produce colonies in soft agar and faster and
bigger subcutaneous or lung tumors. High Sca-1 tumour cells are
more tumorigenic and they are selected in secondary and later
tumors.
We have defined a mechanism that links the known K-Ras
pathway, PI3K-Pdk1 with the previously observed low p38 activity
found in lung adenocarcinomas. Reduced p38 activity allows more
PI3K-Pdk1 signalling, that selects more malignant cells, with a less
differentiated stem-like profile, with expression of Sca-1/CD44/
Sox9 markers. The confirmation of a similar mechanism in human
lung adenocarcinomas provides a further advance in the search of
putative new targets for therapy and detection of more malignant
cells.
Supporting Information
Figure S1 In vitro culture and characterization of K-Ras
transformed cells. (A) Immunofluorescence staining of K-
Ras12 transformed Sca1 sorted cell spheres in culture showing the
expression of epithelial, stem and lung specific markers. (B) Graph
shows qPCR relative mRNA expression of lung specific markers in
freshly isolated, cultured (passage 30) or K-RasG12 infected
(passage 4). (C) Lung stem cells transfected with retrovial vectors
expressing K-RasWT or K-RasG12V. The PCR shows the
expression of p38AGF (dominant negative), or oncogenic K-
RasG12V. (D) Apoptosis of the cell types based on Anexin
detection by flow cytometry. (E) Cell cycle distribution of the
different cell types. (F) Relative mRNA expression of Sox9 in cells
with or without p38 activity.
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Figure S2 In vitro and in vivo characterization of the
functional and molecular properties of the transformed
stem cells. (A) Colony formation in soft agar using K-Ras
transformed lung stem cells in culture or isolated from serial
subcutaneous tumours. Values are depicted as mean 6 standard
error of the mean (SEM) from four different experiments. (B) Sox9
and Cyclin D1 protein expression in K-RasWT or K-RasG12 with
or without p38 activity in culture or cells isolated from serial
tumours. (C) Injected GFP cells in SC tumors do not express the
non-epithelial marker CD73. (D) Injected GFP cells (left) in SC
tumors express the lung specific marker SP-C (right). (E) Detection
of the GFP fluorescence on isolated tumours from subcutaneous
injection of lung stem/progenitor cells expressing K-RasG12 with
or without p38 activity. (F) Lung tumours from tail-vein injected
GFP expressing cells. Each genotype, n = 5. One-Way ANOVA
test p#0.01.
(PDF)
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